Efficacy of erenumab in chronic migraine patients with and without ictal allodynia

Volume: 41, Issue: 11-12, Pages: 1152 - 1160
Published: May 13, 2021
Abstract
Ictal cutaneous allodynia, common in chronic migraine, is associated with reduced responses to acute treatment with triptans. Allodynia's impact on the efficacy of newer preventive treatments such as erenumab is unknown.Post-hoc subgroup analysis of a double-blind, randomized, placebo-controlled 12-week study of erenumab in chronic migraine, contrasting those with no allodynia with those with moderate-severe allodynia assessed with the Allodynia...
Paper Details
Title
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia
Published Date
May 13, 2021
Volume
41
Issue
11-12
Pages
1152 - 1160
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.